Avia Pharma

Executive Summary

Avia Pharma is a Swedish pharmaceutical company founded in 2015 that develops and commercializes both prescription and over-the-counter (OTC) products across five core therapeutic areas: women's health, urology, dermatology, allergy, and general OTC. With a portfolio of over 30 products, the company has established a strong presence in Northern Europe, deriving the majority of its sales from its own branded pharmaceuticals. Avia Pharma leverages drug delivery technologies to differentiate its offerings and address unmet needs in niche markets. Its strategy focuses on organic growth through product line extensions, geographic expansion, and selective in-licensing or acquisition of complementary assets. The company operates as a private entity, which provides flexibility to execute long-term strategies without the pressure of quarterly earnings expectations. Avia Pharma's diversified portfolio across multiple therapeutic areas mitigates risk and provides multiple revenue streams, while its concentration on the Nordic region offers a stable market environment with favorable demographics and healthcare spending. The company's revenue growth and profitability are supported by a disciplined approach to product lifecycle management and cost control. Overall, Avia Pharma represents a well-positioned player in the European specialty pharmaceutical space, with a track record of successful product commercialization and a pipeline that addresses both acute and chronic conditions.

Upcoming Catalysts (preview)

• Q3 2026Launch of new women's health product in Nordic markets80% success
• Q1 2027Regulatory approval for next-generation dermatology treatment65% success
• Q4 2026Partnership or in-licensing deal to expand OTC portfolio70% success